
Sanofi’s chief executive new president elect of EFPIA
pharmafile | November 7, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Chris Viehbacher, Sanofi
European pharma members body the EFPIA has announced that Sanofi’s chief executive Christopher Viehbacher is to stand as its new president elect.
He will take up the position as of June 2013 for a two-year term. Regarding the designation Richard Bergström the director general of EFPIA said: “Chris Viehbacher is well placed to take over the leadership of EFPIA. At this time, it is important to remind ourselves and others what is needed to sustain research based pharmaceuticals in Europe. Chris was involved in the high-level group G10 Medicines and has shown his ability to engage with policy-makers worldwide. I look forward to working with him.”
Christopher Viehbacher added: “I’m extremely honoured by this designation that comes in the midst of a crisis period when high value-added industry such as healthcare sector is what European countries need. There’s a virtuous economic cycle of investing in education and then research and innovation.
“The challenge Europe is currently facing is about managing to reduce government deficits and debt without smothering the opportunity for growth; to make sure that relevant pro-growth, pro-innovation strategies can be activated.”
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






